Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Rev Esp Enferm Dig ; 2024 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-38685905

RESUMEN

Following the growing trend of trying to individualise treatment in inflammatory bowel disease and in view of the challenge posed by elderly patients requiring biologic treatments, we have conducted a study in our centre to assess the T3/T4 index as a predictor of response to biologic treatments in elderly patients.

2.
Int J Med Sci ; 15(1): 10-15, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29333082

RESUMEN

BACKGROUND: The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC). Since receptors for the Fc portion of IgG (FCGRs) are involved in the degradation of IgG complexes, we hypothesised that a polymorphism in FCGR3A (V158F; rs396991) gene could be involved in anti-TNF ADA generation and treatment resistance. MATERIAL AND METHODS: A cohort of 103 IBD patients (80 CD, 23 UC) were genotyped and serum level of both anti-TNFs (infliximab or adalimumab) and ADA against them were measured. RESULTS: No significant differences were observed between ADA occurrence or V158F genotype and type of disease or the kind of anti-TNF administrated. Interestingly, VV genotype correlated with patients producing ADA (VV: 37.5% vs. FV: 10.6% or FF: 5%; p=0.004) and was an independent predictor of this event after multivariate analysis. Moreover, VV genotype also correlated with those patients receiving anti-TNF dose intensification (p=0.03). CONCLUSION: FCGR3A V158F polymorphism seems to be associated with ADA production against mAbs and it could be taken into account when considering the dose and type of anti-TNF in IBD patients.


Asunto(s)
Anticuerpos Antiidiotipos/inmunología , Colitis Ulcerosa/tratamiento farmacológico , Enfermedad de Crohn/tratamiento farmacológico , Fármacos Gastrointestinales/inmunología , Receptores de IgG/genética , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adalimumab/sangre , Adalimumab/inmunología , Adalimumab/uso terapéutico , Adulto , Anticuerpos Antiidiotipos/sangre , Estudios de Cohortes , Colitis Ulcerosa/sangre , Colitis Ulcerosa/genética , Colitis Ulcerosa/inmunología , Enfermedad de Crohn/sangre , Enfermedad de Crohn/genética , Enfermedad de Crohn/inmunología , Femenino , Fármacos Gastrointestinales/uso terapéutico , Humanos , Infliximab/sangre , Infliximab/inmunología , Infliximab/uso terapéutico , Masculino , Persona de Mediana Edad , Polimorfismo Genético , Receptores de IgG/inmunología
3.
Rev Esp Enferm Dig ; 108(10): 670-672, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26887434

RESUMEN

Gastric involvement with the varicella-zoster virus is an uncommon clinical condition where early suspicion and diagnosis are important to prevent the consequences deriving from its high morbidity and mortality, which in immunocompromised patients oscillate between 9% and 41% according to the various series. Two cases of gastric involvement with the varicella-zoster virus (VZV) in two patients with blood cancer are reported below. Gastric lesions are usually preceded by typical papulovesicular skin lesions. When gastric involvement is the first symptom of the disease its diagnosis and management may be delayed, which may entail severe consequences for immunocompromised patients. It is therefore that we suggest its inclusion in the algorithm for immunocompromised patients with abdominal pain and ulcer-like endoscopic lesions.


Asunto(s)
Varicela/complicaciones , Varicela/tratamiento farmacológico , Neoplasias Hematológicas/complicaciones , Gastropatías/complicaciones , Gastropatías/tratamiento farmacológico , Dolor Abdominal , Aciclovir/uso terapéutico , Antivirales/uso terapéutico , Femenino , Humanos , Huésped Inmunocomprometido , Persona de Mediana Edad
4.
Eur J Clin Pharmacol ; 69(3): 431-8, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22960943

RESUMEN

AIM: Inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are partially attributable to an increased secretion of proinflamatory cytokines, such as tumour necrosis factor (TNF) and interleukin-1ß (IL1ß), which play essential roles in the disease pathogenesis and are target molecules for specific therapy. Given the inter-individual variability in the response to the anti-TNF monoclonal antibody infliximab, the aim of our study was to explore the predictive value of TNF and/or IL1ß as surrogate markers of infliximab response. METHODS: Serial serum concentrations of TNF and IL1ß and TNF promoter region and IL1B polymorphisms were determined in 47 patients (29 CD and 18 UC) receiving infliximab and correlated with treatment response. RESULTS: Baseline serum concentrations of TNF and IL1ß were higher in UC patients than in CD patients (p = 0.0097 and 0.0024, respectively). CD patients showing <0.64 pg/ml IL1ß at baseline were more frequently responders than non-responders (p = 0.036), and the C allele of the IL1B polymorphism was associated with higher IL1ß serum concentrations (p = 0.026) and with poorer clinical remission after 14 weeks of infliximab treatment. No significant association was found between serum TNF concentration or TNF polymorphism and patient response to infliximab. CONCLUSION: This is the first study evaluating the pharmacogenetic role of the rs1143634 polymorphism of IL1B and TNF polymorphisms in infliximab-treated IBD patients. We found an association between the rs1143634 C allele and higher serum IL1ß concentrations and a lower response to infliximab treatment in CD patients that warrants the interest of future studies in larger and independent series.


Asunto(s)
Antiinflamatorios/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Colitis Ulcerosa/tratamiento farmacológico , Enfermedad de Crohn/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Mediadores de Inflamación/sangre , Interleucina-1beta/sangre , Interleucina-1beta/genética , Polimorfismo Genético , Factor de Necrosis Tumoral alfa/sangre , Factor de Necrosis Tumoral alfa/genética , Adolescente , Adulto , Biomarcadores/sangre , Colitis Ulcerosa/sangre , Colitis Ulcerosa/genética , Colitis Ulcerosa/inmunología , Enfermedad de Crohn/sangre , Enfermedad de Crohn/genética , Enfermedad de Crohn/inmunología , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Infliximab , Masculino , Fenotipo , Regiones Promotoras Genéticas , Inducción de Remisión , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
5.
Gastroenterol Hepatol ; 30(8): 457-60, 2007 Oct.
Artículo en Español | MEDLINE | ID: mdl-17949612

RESUMEN

Tuberculosis is a common infection worldwide. In developed countries, the incidence of this disease was low until a few years ago. However, due to the rise in immigration and HIV infection, the frequency of tuberculosis has recently shown a marked increase. Although the most frequent location of tuberculosis infection continues to be respiratory, infection in other sites, such as musculoskeletal, genitourinary, neurological and abdominal areas, has recently become more common. Abdominal infection, the most frequently described extrapulmonary localization, commonly affects the spleen, liver, ileocecal region, peritoneum, and regional lymph nodes. Tuberculosis of the pancreas is considered a rare entity.


Asunto(s)
Enfermedades Duodenales/etiología , Fístula Intestinal/etiología , Enfermedades Pancreáticas/complicaciones , Tuberculosis Gastrointestinal/complicaciones , Adulto , Infecciones por VIH/complicaciones , Humanos , Masculino , Enfermedades Pancreáticas/diagnóstico , Tuberculosis Gastrointestinal/diagnóstico
7.
Rev. esp. enferm. dig ; 108(10): 670-672, oct. 2016. ilus
Artículo en Español | IBECS (España) | ID: ibc-156754

RESUMEN

La afectación gástrica por el virus varicela-zóster es una entidad clínica poco frecuente, cuya sospecha y diagnóstico precoz es importante para evitar las consecuencias derivadas de su elevada morbimortalidad que en pacientes inmunocomprometidos varía entre un 9% y 41% según las series. A continuación se describen dos casos de afectación gástrica por el virus de la varicela-zóster (VVZ) en dos pacientes con enfermedad hematooncológica. Habitualmente las lesiones gástricas van precedidas de la aparición de lesiones cutáneas pápulo-vesiculares características. Cuando la afectación gástrica es el primer síntoma de la enfermedad se puede producir un retraso en el diagnóstico y tratamiento de esta infección que puede conllevar consecuencias graves para el paciente inmunocomprometido. Es por ello que proponemos que sea una entidad tenida en cuenta en el algoritmo de estudio del paciente inmunocomprometido que presenta dolor abdominal y lesiones endoscópicas de tipo ulceroso (AU)


Gastric involvement with the varicella-zoster virus is an uncommon clinical condition where early suspicion and diagnosis are important to prevent the consequences deriving from its high morbidity and mortality, which in immunocompromised patients oscillate between 9% and 41% according to the various series. Two cases of gastric involvement with the varicella-zoster virus (VZV) in two patients with blood cancer are reported below. Gastric lesions are usually preceded by typical papulovesicular skin lesions. When gastric involvement is the first symptom of the disease its diagnosis and management may be delayed, which may entail severe consequences for immunocompromised patients. It is therefore that we suggest its inclusion in the algorithm for immunocompromised patients with abdominal pain and ulcer-like endoscopic lesions (AU)


Asunto(s)
Humanos , Varicela/complicaciones , Herpesvirus Humano 3/patogenicidad , Gastritis/virología , Huésped Inmunocomprometido , Úlcera Gástrica/virología , Dolor Abdominal/etiología , Leucemia/complicaciones , Linfoma no Hodgkin/complicaciones
8.
Gastroenterol. hepatol. (Ed. impr.) ; 30(8): 457-460, oct. 2007. ilus
Artículo en Es | IBECS (España) | ID: ibc-62449

RESUMEN

La tuberculosis es una entidad frecuente en todo el mundo. En los países desarrollados se describía hasta hace unos años un descenso en su incidencia, pero debido al aumento de flujos migratorios y a la aparición del sida, se ha detectado un notable aumento en su frecuencia en los últimos tiempos. A pesar de que la localización clásica con afectación pulmonar continúa siendo la forma de presentación más comunicada, se ha descrito un incremento en el diagnóstico en otras localizaciones. La afectación de otros órganos y aparatos, como el sistema muscular esquelético, el genitourinario, el neurológico o el abdominal, ha dejado de ser infrecuente. La abdominal es una localización extrapulmonar cada vez más frecuente, zona en la que se ha descrito una afectación de diversas estructuras: cadenas linfáticas mesentéricas, intestino delgado, peritoneo, hígado y bazo. La afectación pancreática es una entidad muy infrecuente


Tuberculosis is a common infection worldwide. In developed countries, the incidence of this disease was low until a few years ago. However, due to the rise in immigration and HIV infection, the frequency of tuberculosis has recently shown a marked increase. Although the most frequent location of tuberculosis infection continues to be respiratory, infection in other sites, such as musculoskeletal, genitourinary, neurological and abdominal areas, has recently become more common. Abdominal infection, the most frequently described extrapulmonary localization, commonly affects the spleen, liver, ileocecal region, peritoneum, and regional lymph nodes. Tuberculosis of the pancreas is considered a rare entity (AU)


Asunto(s)
Humanos , Masculino , Adulto , Tuberculosis/diagnóstico , Fístula Intestinal/diagnóstico , Enfermedades Pancreáticas/diagnóstico , Mycobacterium tuberculosis/aislamiento & purificación , Mycobacterium tuberculosis/patogenicidad , Infecciones por VIH/complicaciones , Infecciones Oportunistas Relacionadas con el SIDA/diagnóstico , Biomarcadores/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA